{"": [198, 2794, 0], "1. Introduction": [2795, 11410, 0], "2.1. Design": [11437, 12050, 0], "2.2. Participants": [12051, 13129, 0], "2.3. Instrument": [13130, 14446, 0], "2.4. Ethics": [14447, 15511, 0], "2.5. Analysis": [15512, 16930, 0], "2.6. Pooled Analysis of Results of CoVaST Project Studies Conducted in Central Europe": [16931, 17375, 0], "2. Materials and Methods": [11411, 17375, 1], "3.1. Demographic Characteristics": [17388, 18743, 0], "3.2. Medical Anamnesis": [18744, 20162, 0], "3.3. COVID-19-Related Anamnesis": [20163, 20637, 0], "3.4. Local Side Effects": [20638, 21690, 0], "3.5. Systemic SRAEs": [21691, 23070, 0], "3.6. Orofacial and Skin-Related SRAEs": [23071, 23892, 0], "3.7. Over the Counter, Alleviating Drugs Taken after Vaccination": [23893, 24468, 0], "3.8. COVID-19 Vaccines SRAEss by Gender": [24469, 25993, 0], "3.9. COVID-19 Vaccines SRAEs by Age": [25994, 27549, 0], "3.10. Predictors of SRAEs of COVID-19 Vaccines": [27550, 29107, 0], "3.11. Pooled Analysis Results from CoVAST Studies Conducted in Czech Republic, Slovakia, Germany, and Poland": [29108, 29841, 0], "3. Results": [17376, 29841, 1], "4.1. Strengths and Limitations": [43700, 46055, 0], "4.2. Implications": [46056, 48670, 0], "4. Discussion": [29842, 48670, 1], "5. Conclusions": [48671, 50184, 0]}